Illumina Chosen to Enhance Precision Medicine in Everyday Singapore Healthcare

Illumina Announced as Key Player in Precise Medicine Journey in Singapore

In a historic move towards integrating precision medicine into everyday healthcare, Illumina, Inc. has been selected to provide whole-genome sequencing services for the ambitious SG-INSIGHT study. This initiative is a pioneering cohort within Phase III of Singapore's National Precision Medicine (NPM) programme, expected to encompass nearly one in ten residents, approximately 450,000 individuals.

The SG-INSIGHT study aims to generate vital evidence from genomic and health data to establish preventive approaches that can significantly enhance healthcare outcomes in Singapore. This shift signifies a pivotal transition from a traditional focus on healthy volunteers to an inclusive approach that investigates a wide range of medical conditions, thereby enabling a more comprehensive understanding of disease mechanisms and treatment effectiveness.

By linking genomic data with real-world health outcomes, the SG-INSIGHT study seeks to provide insights that will help shape the implementation of genetic screening within Singapore's public healthcare landscape. Jacob Thaysen, CEO of Illumina, articulated the visionary essence of this programme, stating, "Singapore is showing what the future of precision medicine can look like on a national scale. This initiative opens doors to a deeper understanding of diseases, enabling healthcare providers to make informed and timely decisions that facilitate earlier interventions."

This significant undertaking builds upon nearly a decade of momentum in precision medicine efforts in Singapore. According to Professor Patrick Tan, Executive Director of PRECISE, the SG-INSIGHT initiative endeavors to extend knowledge regarding how genetic, lifestyle, and environmental factors intertwine to influence health and disease patterns. Notably, the Phase III aims to cultivate a reliable and sustainable precision health ecosystem that resonates with the diverse needs of Singapore’s population.

Illumina will carry out the sequencing process through its state-of-the-art genomics facility located in Singapore, where sample preparation, sequencing, and data analytics will be meticulously managed by dedicated scientific and bioinformatics teams. This facility, co-located with Illumina’s manufacturing and research initiatives, demonstrates the company’s unwavering commitment to quality and compliance with Singapore's Healthcare Services Act 2020.

The competitive tender that secured Illumina’s involvement in the SG-INSIGHT study reflects the company’s longstanding engagement in advancing genomics in Singapore, having previously supported the successful delivery of NPM Phase II, which studied over 100,000 genomes of healthy volunteers. This continuity of collaboration underscores the robustness of Illumina's relationship with local healthcare initiatives.

As one of Illumina's most critical innovation centers in the Asia Pacific region since its establishment in Singapore in 2008, the company now boasts a workforce of over 1,700 across multiple locations in the country. Its Singapore operations form a vital hub encompassing commercial, manufacturing, and research functions, thereby influencing the global landscape of genomics and sequencing technologies.

Illumina's efforts, in partnership with PRECISE, are poised to significantly impact public health strategies, pushing the boundaries of how genomic insights can translate to tangible health benefits for individuals. By investing in deeply rooted technological and human resources, Illumina is dedicated to fostering responsible advancements in genomics that align with Singapore’s healthcare ambitions.

About PRECISE

Precision Health Research, Singapore (PRECISE) orchestrates Singapore's National Precision Medicine programme, engaging various research, clinical, and industrial partners to foster understanding and improve health outcomes based on genomic insights. The programme is integral to Singapore's vision for innovation in healthcare, underscoring a commitment to driving progress in precision medicine.

For more information on Illumina's groundbreaking work and its contributions to precision medicine in Singapore, visit illumina.com.